How to minimize pterygium recurrence rates: clinical perspectives

Raffaele Nuzzi, Federico Tridico, Raffaele Nuzzi, Federico Tridico

Abstract

The main treatment for pterygium is surgical removal. However, pterygium surgery is concerned with high rates of postoperative recurrence. Predicting factors of recurrence are not fully understood, yet, but they probably depend on a multitude of patient-related, clinical, and/or surgical factors. Several adjuvant treatments have been proposed to reduce postoperative pterygium recurrence, including different antimetabolites, antiangiogenetic factors, and radiation therapy. The purpose of this review is to collect the current evidence regarding application and limits of different therapeutic approaches for preventing postoperative recurrence of pterygium, giving insights and perspectives for better management of this disease. In the light of the current evidence, pterygium surgery cannot disregard wound coverage with conjunctival autografting or rotational flap combined with adjuvant treatments. The rotational flap technique is associated with shorter surgical time rates and prevents graft displacement and necrosis, given its vascular pedicle. Amniotic membrane may still be reserved in case of great conjunctival defects or insufficient conjunctiva. Repeated subconjunctival antivascular endothelial growth factor injections can be considered as an effective and safe adjuvant treatment. Moreover, management of postoperative pain is crucial. Innovative treatment strategies will probably target different molecular pathways, considering recent findings regarding pterygium pathogenesis, to improve better understanding and develop universally shared guidelines. Great importance shall be dedicated to the identification of novel molecular biomarkers and favoring factors of recurrence, in order to achieve a customized surgical treatment for each patient and obtain maximal reduction of postoperative recurrence.

Keywords: adjuvant therapy; amniotic membrane; conjunctival autograft; predicting factors; pterygium; rotational flap.

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Postoperative results of a rotational flap, transposed from the inferior conjunctiva, with its vascular pedicle.

References

    1. Dushku N, John MK, Schultz GS, Reid TW. Pterygia pathogenesis: corneal invasion by matrix metalloproteinase expressing altered limbal epithelial basal cells. Arch Ophthalmol. 2001;119(5):695–706.
    1. Aspiotis M, Tsanou E, Gorezis S, et al. Angiogenesis in pterygium: study of microvessel density, vascular endothelial growth factor, and thrombospondin-1. Eye. 2007;21(8):1095–1101.
    1. Kase S, Osaki M, Jin XH, et al. Increased expression of erythropoietin receptor in human pterygial tissues. Int J Mol Med. 2007;20(5):699–702.
    1. Tsai YY, Chiang CC, Yeh KT, Lee H, Cheng YW. Effect of TIMP-1 and MMP in pterygium invasion. Invest Ophthalmol Vis Sci. 2010;51(7):3462–3467.
    1. Liang K, Jiang Z, Ding BQ, Cheng P, Huang DK, Tao LM. Expression of cell proliferation and apoptosis biomarkers in pterygia and normal conjunctiva. Mol Vis. 2011;17:1687–1693.
    1. Coroneo MT. Pterygium as an early indicator of ultraviolet insolation: a hypothesis. Br J Ophthalmol. 1993;77(11):734–739.
    1. Hilgers JH. Pterygium: its incidence, heredity and etiology. Am J Ophthalmol. 1960;50(4):635–644.
    1. Marchetti C, Sidahmed-Adrar N, Collin F, Jore D, Gardès-Albert M, Bonnefont-Rousselot D. Melatonin protects PLPC liposomes and LDL towards radical-induced oxidation. J Pineal Res. 2011;51(3):286–296.
    1. Kau HC, Tsai CC, Lee CF, et al. Increased oxidative DNA damage, 8-hydroxydeoxy-guanosine, in human pterygium. Eye. 2006;20(7):826–831.
    1. Balci M, Sahin S, Mutlu FM, Yağci R, Karanci P, Yildiz M. Investigation of oxidative stress in pterygium tissue. Mol Vis. 2011;17:443–447.
    1. Reid TW, Dushku N. Does human papillomavirus cause pterygium? Br J Ophthalmol. 2003;87(7):806–808.
    1. Di Girolamo N. Association of human papilloma virus with pterygia and ocular-surface squamous neoplasia. Eye. 2012;26(2):202–211.
    1. Detorakis ET, Drakonaki EE, Spandidos DA. Molecular genetic alterations and viral presence in ophthalmic pterygium. Int J Mol Med. 2000;6(1):35–41.
    1. Cárdenas-Cantú E, Zavala J, Valenzuela J, Valdez-García JE. Molecular basis of pterygium development. Semin Ophthalmol. 2016;31(6):567–583.
    1. Di Girolamo N, Chui J, Coroneo MT, Wakefield D. Pathogenesis of pterygia: role of cytokines, growth factors, and matrix metalloproteinases. Prog Retin Eye Res. 2004;23(2):195–228.
    1. Di Girolamo N, Kumar RK, Coroneo MT, Wakefield D. UVB-mediated induction of interleukin-6 and -8 in pterygia and cultured human pterygium epithelial cells. Invest Ophthalmol Vis Sci. 2002;43(11):3430–3437.
    1. Siak JJK, Ng SL, Seet LF, Beuerman RW, Tong L. The nuclear-factor κB pathway is activated in pterygium. Invest Ophthalmol Vis Sci. 2011;52(1):230–236.
    1. Pinkerton OD, Hokama Y, Shigemura LA. Immunologic basis for the pathogenesis of pterygium. Am J Ophthalmol. 1984;98(2):225–228.
    1. Ling S, Liang L, Lin H, Li W, Xu J. Increasing lymphatic microvessel density in primary pterygia. Arch Ophthalmol. 2012;130(6):735–742.
    1. Jin J, Guan M, Sima J, et al. Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor levels in pterygia. Cornea. 2003;22(5):473–477.
    1. Riau AK, Wong TT, Lan W, et al. Aberrant DNA methylation of matrix remodeling and cell adhesion related genes in pterygium. PLoS One. 2011;6(2):e14687.
    1. Kria L, Ohira A, Amemiya T. Immunohistochemical localization of basic fibroblast growth factor, platelet derived growth factor, transforming growth factor-beta and tumor necrosis factor-alpha in the pterygium. Acta Histochem. 1996;98(2):195–201.
    1. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86(3):353–364.
    1. Park CY, Choi JS, Lee SJ, Hwang SW, Kim EJ, Chuck RS. Cyclooxygenase-2-expressing macrophages in human pterygium co-express vascular endothelial growth factor. Mol Vis. 2011;17:3468–3480.
    1. Solomon A, Grueterich M, Li DQ, Meller D, Lee SB, Tseng SC. Overexpression of insulin-like growth factor-binding protein-2 in pterygium body fibroblasts. Invest Ophthalmol Vis Sci. 2003;44(2):573–580.
    1. Ye J, Song YS, Kang SH, Yao K, Kim JC. Involvement of bone marrow-derived stem and progenitor cells in the pathogenesis of pterygium. Eye. 2004;18(8):839–843.
    1. Song YS, Ryu YH, Choi SR, Kim JC. The involvement of adult stem cells originated from bone marrow in the pathogenesis of pterygia. Yonsei Med J. 2005;46(5):687–692.
    1. Peiretti E, Dessì S, Mulas C, et al. Modulation of cholesterol homeostasis by antiproliferative drugs in human pterygium fibroblasts. Invest Ophthalmol Vis Sci. 2007;48(8):3450–3458.
    1. Anguria P, Kitinya J, Ntuli S, Carmichael T. The role of heredity in pterygium development. Int J Ophthalmol. 2014;7(3):563–573.
    1. Mohammed I. Treatment of pterygium. Ann Afr Med. 2011;10(3):197–203.
    1. Fernandes M, Sangwan VS, Bansal AK, et al. Outcome of pterygium surgery: analysis over 14 years. Eye. 2005;19(11):1182–1190.
    1. Hovanesian JA, Starr CE, Vroman DT, The ASCRS Cornea Clinical Committee Surgical techniques and adjuvants for the management of primary and recurrent pterygia. J Cataract Refract Surg. 2017;43(3):405–419.
    1. Rohrbach IM, Starc S, Knorr M. Vorhersage von Pterygiumrezidiven Aufgrund Morphologischer und Immunhistologischer Parameter [Predicting recurrent pterygium based on morphologic and immunohistologic parameters] Ophthalmologe. 1995;92(4):463–468.
    1. Kim KW, Kim JC. Current approaches and future directions in the management of pterygium. Int J Ophthalmol. 2018;11(5):709–711.
    1. Tan DT, Chee SP, Dear KB, Lim AS. Effect of pterygium morphology on pterygium recurrence in a controlled trial comparing conjunctival autografting with bare sclera excision. Arch Ophthalmol. 1997;115(10):1235–1240.
    1. Kim KW, Park SH, Kim JC. Fibroblast biology in pterygia. Exp Eye Res. 2016;142:32–39.
    1. Kaufman SC, Jacobs DS, Lee WB, Deng SX, Rosenblatt MI, Shtein RM. Options and adjuvants in surgery for pterygium: a report by the American Academy of Ophthalmology. Ophthalmology. 2013;120(1):201–208.
    1. Sánchez-Thorin JC, Rocha G, Yelin JB. Meta-analysis on the recurrence rates after bare sclera resection with and without mitomycin C use and conjunctival autograft placement in surgery for primary pterygium. Br J Ophthalmol. 1998;82(6):661–665.
    1. Kenyon KR, Wagoner MD, Hettinger ME. Conjunctival autograft transplantation for advanced and recurrent pterygium. Ophthalmology. 1985;92(11):1461–1470.
    1. Bilge AD. Comparison of conjunctival autograft and conjunctival transposition flap techniques in primary pterygium surgery. Saudi J Ophthalmol. 2018;32(2):110–113.
    1. Koranyi G, Seregard S, Kopp ED. The cut-and-paste method for primary pterygium surgery: long-term follow-up. Acta Ophthalmol Scand. 2005;83(3):298–301.
    1. Ma DH, See LC, Liau SB, Tsai RJ. Amniotic membrane graft for primary pterygium: comparison with conjunctival autograft and topical mitomycin C treatment. Br J Ophthalmol. 2000;84(9):973–978.
    1. Al Fayez MF. Limbal versus conjunctival autograft transplantation for advanced and recurrent pterygium. Ophthalmology. 2002;109(9):1752–1755.
    1. Cornelius CR. Recurrence rate and complications of pterygium extended removal followed by extended conjunctival transplant. Cornea. 2017;36(1):101–103.
    1. Kumar S, Singh R. Pterygium excision and conjunctival autograft: a comparative study of techniques. Oman J Ophthalmol. 2018;11(2):124–128.
    1. Cohen RA, McDonald MB. Fixation of conjunctival autografts with an organic tissue adhesive. Arch Ophthalmol. 1993;111(9):1167–1168.
    1. Koranyi G, Seregard S, Kopp ED. Cut and paste: a no suture, small incision approach to pterygium surgery. Br J Ophthalmol. 2004;88(7):911–914.
    1. Romano V, Cruciani M, Conti L, Fontana L. Fibrin glue versus sutures for conjunctival autografting in primary pterygium surgery. Cochrane Database Syst Rev. 2016;12(4):CD011308.
    1. Ratnalingam V, Eu AL, Ng GL, Taharin R, John E. Fibrin adhesive is better than sutures in pterygium surgery. Cornea. 2010;29(5):485–489.
    1. Uy HS, Reyes JM, Flores JD, Lim-Bon-Siong R. Comparison of fibrin glue and sutures for attaching conjunctival autografts after pterygium excision. Ophthalmology. 2005;112(4):667–671.
    1. Celik T. In situ blood coagulum versus sutures for autograft fixation after pterygium excision. Curr Eye Res. 2018;43(8):977–980.
    1. Kurian A, Reghunadhan I, Nair KG. Autologous blood versus fibrin glue for conjunctival autograft adherence in sutureless pterygium surgery: a randomised controlled trial. Br J Ophthalmol. 2015;99(4):464–470.
    1. Choudhury S, Dutta J, Mukhopadhyay S, et al. Comparison of autologous in situ blood coagulum versus sutures for conjunctival autografting after pterygium excision. Int Ophthalmol. 2014;34(1):41–48.
    1. Natung T, Keditsu A, Shullai W, Goswami PK, Sutureless GPK. Sutureless, glue-less conjunctival autograft versus conjunctival autograft with sutures for primary, advanced pterygia: an interventional pilot study. J Clin Diagn Res. 2017;11(8):NC04–NC07.
    1. Lešin M, Paradžik M, Marin Lovrić J, et al. Cauterisation versus fibrin glue for conjunctival autografting in primary pterygium surgery (CAGE CUP): study protocol of a randomised controlled trial. BMJ Open. 2018;8(6):e020714.
    1. Küçükerdönmez C, Akova YA, Altinörs DD. Comparison of conjunctival autograft with amniotic membrane transplantation for pterygium surgery: surgical and cosmetic outcome. Cornea. 2007;26(4):407–413.
    1. Vrabec MP, Weisenthal RW, Elsing SH. Subconjunctival fibrosis after conjunctival autograft. Cornea. 1993;12(2):181–183.
    1. Mullins JB, Holds JB, Branham GH, Thomas JR. Complications of the transconjunctival approach. A review of 400 cases. Arch Otolaryngol Head Neck Surg. 1997;123(4):385–388.
    1. Ferry AP. Pyogenic granulomas of the eye and ocular adnexa: a study of 100 cases. Trans Am Ophthalmol Soc. 1989;87:327–343.
    1. Zhang Z, Yang Z, Pan Q, Chen P, Guo L. Clinicopathologic characteristics and the surgical outcome of conjunctival granulomas after pterygium surgery. Cornea. 2018;37(8):1008–1012.
    1. Kapadia SB, Heffner DK. Pitfalls in the histopathologic diagnosis of pyogenic granuloma. Eur Arch Otorhinolaryngol. 1992;249(4):195–200.
    1. Lindquist TP, Lee WB. Mitomycin C-associated scleral stromalysis after pterygium surgery. Cornea. 2015;34(4):398–401.
    1. Zloto O, Rosen N, Leshno A, Rosner M. Very long term success of pterygium surgery with conjunctival graft. Cont Lens Anterior Eye. 2017;40(4):267–269.
    1. Koç F, Demirbay P, Teke MY. Primer ve rekürren pterygiumda konjonktival otogreftleme. T Oft Gaz. 2002:583–588.
    1. Syam PP, Eleftheriadis H, Liu CS. Inferior conjunctival autograft for primary pterygia. Ophthalmology. 2003;110(4):806–810.
    1. Paracha Q, Ayoob M, Dawood Z, Mirza SA. Recurrence rate with use of intraoperative mitomycin C versus conjunctival autograft following pterygium excision. Pak J Med Sci. 2014;30(6):1243–1246.
    1. Keklikci U, Celik Y, Cakmak SS, Unlu MK, Bilek B. Conjunctival-limbal autograft, amniotic membrane transplantation, and intraoperative mitomycin C for primary pterygium. Ann Ophthalmol. 2007;39(4):296–301.
    1. Tananuvat N, Martin T. The results of amniotic membrane transplantation for primary pterygium compared with conjunctival autograft. Cornea. 2004;23(5):458–463.
    1. Frucht-Pery J, Raiskup F, Ilsar M, Landau D, Orucov F, Solomon A. Conjunctival autografting combined with low-dose mitomycin C for prevention of primary pterygium recurrence. Am J Ophthalmol. 2006;141(6):1044–1050.
    1. Segev F, Jaeger-Roshu S, Gefen-Carmi N, Assia EI. Combined mitomycin C application and free flap conjunctival autograft in pterygium surgery. Cornea. 2003;22(7):598–603.
    1. Tseng SC, Li DQ, Ma X. Suppression of transforming growth factor-beta isoforms, TGF-beta receptor type II, and myofibroblast differentiation in cultured human corneal and limbal fibroblasts by amniotic membrane matrix. J Cell Physiol. 1999;179(3):325–335.
    1. Lee SB, Li DQ, Tan DT, Meller DC, Tseng SC. Suppression of TGF-beta signaling in both normal conjunctival fibroblasts and pterygial body fibroblasts by amniotic membrane. Curr Eye Res. 2000;20(4):325–334.
    1. Prabhasawat P, Barton K, Burkett G, Tseng SC. Comparison of conjunctival autografts, amniotic membrane grafts, and primary closure for pterygium excision. Ophthalmology. 1997;104(6):974–985.
    1. Sangwan VS, Burman S, Tejwani S, Mahesh SP, Murthy R. Amniotic membrane transplantation: a review of current indications in the management of ophthalmic disorders. Indian J Ophthalmol. 2007;55(4):251–260.
    1. Thatte S. Amniotic membrane transplantation: an option for ocular surface disorders. Oman J Ophthalmol. 2011;4(2):67–72.
    1. Arain MA, Yaqub MA, Ameen SS, Iqbal Z, Naqvi AH, Niazi MK. Amniotic membrane transplantation in primary pterygium compared with bare sclera technique. J Coll Physicians Surg Pak. 2012;22(7):440–443.
    1. Moreno-López R. Estudio comparativo entre escisión de pterigión primario con autoinjerto conjuntival, membrana amniótica y cierre primario [Comparative study between primary pterygium excision using conjunctival autograft, amniotic membrane, and primary closure] Rev Mex Oftalmol. 2004;78:291–297.
    1. Solomon A, Pires RT, Tseng SC. Amniotic membrane transplantation after extensive removal of primary and recurrent pterygia. Ophthalmology. 2001;108(3):449–460.
    1. Clearfield E, Hawkins BS, Kuo IC. Conjunctival autograft versus amniotic membrane transplantation for treatment of pterygium: findings from a Cochrane systematic review. Am J Ophthalmol. 2017;182:8–17.
    1. Tananuvat N, Martin T. The results of amniotic membrane transplantation for primary pterygium compared with conjunctival autograft. Cornea. 2004;23(5):458–463.
    1. Özer A, Yıldırım N, Erol N, Yurdakul S. Long-term results of bare sclera, limbal-conjunctival autograft and amniotic membrane graft techniques in primary pterygium excisions. Ophthalmologica. 2009;223(4):269–273.
    1. Keklikci U, Celik Y, Cakmak SS, Unlu MK, Bilek B. Conjunctival-limbal autograft, amniotic membrane transplantation, and intraoperative mitomycin C for primary pterygium. Ann Ophthalmol. 2007;39(4):296–301.
    1. Besharati MR, Miratashi SA, Ahmadi AB. Pterygium surgery: amniotic membrane or conjunctival autograft transplantation. Int J Ophthalmol. 2006;6:1258–1262.
    1. Hao Y, Ma DH, Hwang DG, Kim WS, Zhang F. Identification of antiangiogenic and antiinflammatory proteins in human amniotic membrane. Cornea. 2000;19(3):348–352.
    1. Bultmann S, You L, Spandau U. Amniotic membrane downregulates chemokine expression in human keratocytes. Investig Ophthalmol Vis Sci. 1999;40:S578.
    1. Tseng SC, Li DQ, Ma X. Suppression of transforming growth factor-beta isoforms, TGF-beta receptor type II, and myofibroblast differentiation in cultured human corneal and limbal fibroblasts by amniotic membrane matrix. J Cell Physiol. 1999;179(3):325–335.
    1. Ye J, Kook KH, Yao K. Temporary amniotic membrane patch for the treatment of primary pterygium: mechanisms of reducing the recurrence rate. Graefes Arch Clin Exp Ophthalmol. 2006;244(5):583–588.
    1. Katırcıoglu YA, Altiparmak U, Engur Goktas S, Cakir B, Singar E, Ornek F. Comparison of two techniques for the treatment of recurrent pterygium: amniotic membrane vs conjunctival autograft combined with mitomycin C. Semin Ophthalmol. 2015;30(5–6):321–327.
    1. Amano S, Motoyama Y, Oshika T, Eguchi S, Eguchi K. Comparative study of intraoperative mitomycin C and beta irradiation in pterygium surgery. Br J Ophthalmol. 2000;84(6):618–621.
    1. Rosen R. Amniotic membrane grafts to reduce pterygium recurrence. Cornea. 2018;37(2):189–193.
    1. Cho H, Chuck RS. Pterygium excision and placement of amniotic membrane grafts. In: Hovanesian JA, editor. Pterygium: Techniques and Technologies for Surgical Success. Thorofare, NJ: Slack Inc; 2012. pp. 91–100.
    1. Ghanavati SZ, Shousha MA, Betancurt C, Perez VL. Combined conjunctival autograft and overlay amniotic membrane transplantation; a novel surgical treatment for pterygium. J Ophthalmic Vis Res. 2014;9(3):399–403.
    1. Shimazaki J, Kosaka K, Shimmura S, Tsubota K. Amniotic membrane transplantation with conjunctival autograft for recurrent pterygium. Ophthalmology. 2003;110(1):119–124.
    1. Pan X, Zhang D, Jia Z, Chen Z, Su Y. Comparison of hyperdry amniotic membrane transplantation and conjunctival autografting for primary pterygium. BMC Ophthalmol. 2018;18(1):119.
    1. Okabe M, Kitagawa K, Yoshida T, et al. Hyperdry human amniotic membrane is useful material for tissue engineering: physical, morphological properties, and safety as the new biological material. J Biomed Mater Res A. 2014;102(3):862–870.
    1. Allen CL, Clare G, Stewart EA, et al. Augmented dried versus cryopreserved amniotic membrane as an ocular surface dressing. PLoS One. 2013;8(10):e78441.
    1. McCoombes JA, Hirst LW, Isbell GP. Sliding conjunctival flap for the treatment of primary pterygium. Ophthalmology. 1994;101(1):169–173.
    1. Alpay A, Uğurbas SH, Erdogan B. Comparing techniques for pterygium surgery. Clin Ophthalmol. 2009;3:69–74.
    1. Bamdad S, Kooshki AS, Yasemi M. Surgical outcome of conjunctival rotational autograft-mitomycin C (MMC) versus free conjunctival autograft-MMC for pterygium removal: a randomized clinical trial. Electron Physician. 2017;9(12):5877–5884.
    1. Dadeya S, Malik KP, Gulliani BP. Pterygium surgery: conjunctival rotation autograft versus conjunctival autograft. Ophthalmic Surg Lasers. 2002;33:269–274.
    1. Wu WK, Wong VW, Chi SC, Lam DS. Surgical management of double-head pterygium by using a novel technique: conjunctival rotational autograft combined with conjunctival autograft. Cornea. 2007;26(9):1056–1059.
    1. Jap A, Chan C, Lim L, Tan DT. Conjunctival rotation autograft for pterygium. An alternative to conjunctival autografting. Ophthalmology. 1999;106(1):67–71.
    1. Young AL, Tam PM, Leung GY, Cheng LL, Lam PT, Lam DS. Prospective study on the safety and efficacy of combined conjunctival rotational autograft with intraoperative 0.02% mitomycin C in primary pterygium excision. Cornea. 2009;28(2):166–169.
    1. Almond MC, Dastrup BT, Kaufman SC. 5-Fluorouracil and mitomycin C: adjuncts to pterygium surgery. In: Hovanesian JA, editor. Pterygium: Techniques and Technologies for Surgical Success. Thorofare, NJ: Slack Inc; 2012. pp. 55–64.
    1. Hayasaka S, Noda S, Yamamoto Y, Setogawa T. Postoperative instillation of low-dose mitomycin C in the treatment of primary pterygium. Am J Ophthalmol. 1988;106(6):715–718.
    1. Frucht-Pery J, Ilsar M, Hemo I. Single dosage of mitomycin C for prevention of recurrent pterygium: preliminary report. Cornea. 1994;13(5):411–413.
    1. Mahar PS. Conjunctival autograft versus topical mitomycin C in treatment of pterygium. Eye. 1997;11(Pt 6):790–792.
    1. Manning CA, Kloess PM, Diaz MD, Yee RW. Intraoperative mitomycin in primary pterygium excision. A prospective, randomized trial. Ophthalmology. 1997;104(5):844–848.
    1. Sharma A, Gupta A, Ram J, Gupta A. Low-dose intraoperative mitomycin-C versus conjunctival autograft in primary pterygium surgery: long term follow-up. Ophthalmic Surg Lasers. 2000;31(4):301–307.
    1. Keklikci U, Celik Y, Cakmak SS, Unlu MK, Bilek B. Conjunctival-limbal autograft, amniotic membrane transplantation, and intraoperative mitomycin C for primary pterygium. Ann Ophthalmol. 2007;39(4):296–301.
    1. Ari S, Caca I, Yildiz ZÖ, Sakalar YB, Dogan E. Comparison of mitomycin C and limbal-conjunctival autograft in the prevention of pterygial recurrence in Turkish patients: a one-year, randomized, assessor-masked, controlled trial. Curr Ther Res Clin Exp. 2009;70(4):274–281.
    1. Biswas MC, Shaw C, Mandal R. Treatment of pterygium with conjunctival limbal autograft and mitomycin C – a comparative study. J Indian Med Assoc. 2007;105(4):200, 202, 204.
    1. Koranyi G, Artzén D, Seregard S, Kopp ED. Intraoperative mitomycin C versus autologous conjunctival autograft in surgery of primary pterygium with four-year follow-up. Acta Ophthalmol. 2012;90(3):266–270.
    1. Cardillo JA, Alves MR, Ambrosio LE, Poterio MB, Jose NK. Single intraoperative application versus postoperative mitomycin C eye drops in pterygium surgery. Ophthalmology. 1995;102(12):1949–1952.
    1. Helal M, Messiha N, Amayem A, El-Maghraby A, Elsherif Z, Dabees M. Intraoperative mitomycin-C versus postoperative topical mitomycin-C drops for the treatment of pterygium. Ophthalmic Surg Lasers. 1996;27(8):674–678.
    1. Hosal BM, Gürsel E. Mitomycin-C for prevention of recurrent pterygium. Ann Ophthalmol. 2000;32(2):107–109.
    1. Oguz H, Basar E, Gurler B. Intraoperative application versus postoperative mitomycin C eye drops in pterygium surgery. Acta Ophthalmol Scand. 1999;77(2):147–150.
    1. Frucht-Pery J, Ilsar M. The use of low-dose mitomycin C for prevention of recurrent pterygium. Ophthalmology. 1994;101(4):759–762.
    1. Dougherty PJ, Hardten DR, Lindstrom RL. Corneoscleral melt after pterygium surgery using a single intraoperative application of mitomycin-C. Cornea. 1996;15(5):537–540.
    1. Dushinsky R, Pleven E, Heidelberger C. The synthesis of 5-fluoropy-rimidines. J Am Chem Soc. 1957;79:4559–4560.
    1. Smith S, D’Amore PA, Dreyer EB. Comparative toxicity of mitomycin C and 5-fluorouracil in vitro. Am J Ophthalmol. 1994;118(3):332–337.
    1. Valezi VG, Schellini SA, Hata Viveiros MM, Padovani CR. Segurança e efetividade no tratamento do pterígio usando infiltração de 5-fluoruracila no intraoperatorio [Safety and efficacy of intraoperative 5-fluorouracil infiltration in pterygium treatment] Arq Bras Oftalmol. 2009;72:169–173. Portuguese.
    1. Akarsu C, Taner P, Ergin A. 5-Fluorouracil as chemoadjuvant for primary pterygium surgery: preliminary report. Cornea. 2003;22(6):522–526.
    1. Pikkel J, Porges Y, Ophir A. Halting pterygium recurrence by postoperative 5-fluorouracil. Cornea. 2001;20(2):168–171.
    1. Prabhasawat P, Tesavibul N, Leelapatranura K, Phonjan T. Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium. Ophthalmology. 2006;113(7):1102–1109.
    1. Galentine P, Sloas H, Hargett N, Cupples HP. Bilateral cicatricial ectropion following topical administration of 5-fluorouracil. Ann Ophthalmol. 1981;13(5):575–577.
    1. Caravella LP, Burns JA, Zangmeister M. Punctal-canalicular stenosis related to systemic fluorouracil therapy. Arch Ophthalmol. 1981;99(2):284–286.
    1. Hickey-Dwyer M, Wishart PK. Serious corneal complication of 5-fluorouracil. Br J Ophthalmol. 1993;77(4):250–251.
    1. Weinreb RN. Adjusting the dose of 5-fluorouracil after filtration surgery to minimize side effects. Ophthalmology. 1987;94(5):564–570.
    1. Burk A. Die Behandlung der Homhaut epitheliome durch Rontgen-strahlen. Strahlenther Onkol. 1912;1:168–171.
    1. Jaros PA, Deluise VP. Pingueculae and pterygium. Surv Ophthalmol. 1988;32:41–49.
    1. Jürgenliemk-Schulz IM, Hartman LJ, Roesink JM, et al. Prevention of pterygium recurrence by postoperative single-dose beta-irradiation: a prospective randomized clinical double-blind trial. Int J Radiat Oncol Biol Phys. 2004;59(4):1138–1147.
    1. De Keizer RJ. Pterygium excision with or without postoperative irradiation, a double-blind study. Doc Ophthalmol. 1982;52(3–4):309–315.
    1. Paryani SB, Scott WP, Wells JW, et al. Management of pterygium with surgery and radiation therapy. The North Florida Pterygium Study Group. Int J Radiat Oncol Biol Phys. 1994;28(1):101–103.
    1. Brenner DJ, Merriam GR. Postoperative irradiation for pterygium: guidelines for optimal treatment. Int J Radiat Oncol Biol Phys. 1994;30(3):721–725.
    1. Bahrassa F, Datta R. Postoperative beta radiation treatment of pterygium. Int J Radiat Oncol Biol Phys. 1983;9(5):679–684.
    1. Beyer DC. Pterygia: single-fraction postoperative beta irradiation. Radiology. 1991;178(2):569–571.
    1. Cooper JS. Postoperative irradiation of pterygia: ten more years of experience. Radiology. 1978;128(3):753–756.
    1. Wilder RB, Buatti JM, Kittelson JM, et al. Pterygium treated with excision and postoperative beta irradiation. Int J Radiat Oncol Biol Phys. 1992;23(3):533–537.
    1. Khalfaoui T, Mkannez G, Colin D, et al. Immunohistochemical analysis of vascular endothelial growth factor (VEGF) and p53 expression in pterygium from Tunisian patients. Pathol Biol. 2011;59(3):137–141.
    1. Teng CC, Patel NN, Jacobson L. Effect of subconjunctival bevacizumab on primary pterygium. Cornea. 2009;28(4):468–470.
    1. Mansour AM. Regression of inflamed pterygia by frequent high-dose intralesional ziv-aflibercept. Cornea. 2017;36(8):1002–1005.
    1. Shenasi A, Mousavi F, Shoa-Ahari S, Rahimi-Ardabili B, Fouladi RF. Subconjunctival bevacizumab immediately after excision of primary pterygium: the first clinical trial. Cornea. 2011;30(11):1219–1222.
    1. Razeghinejad MR, Banifatemi M. Subconjunctival bevacizumab for primary pterygium excision; a randomized clinical trial. J Ophthalmic Vis Res. 2014;9(1):22–30.
    1. Shahin MM, Elbendary AM, Elwan MM, Maha M, Amal M, Mohamed M. Intraoperative subconjunctival bevacizumab as an adjunctive treatment in primary pterygium: a preliminary report. Ophthalmic Surg Lasers Imaging. 2012;43(6):459–466.
    1. Stival LR, Lago AM, Figueiredo MN, Bittar RH, Machado ML, Nassaralla Junior JJ. Efficacy and safety of subconjunctival bevacizumab for recurrent pterygium. Arq Bras Oftalmol. 2014;77(1):4–7.
    1. Nuzzi R, Tridico F. Efficacy of subconjunctival bevacizumab injections before and after surgical excision in preventing pterygium recurrence. J Ophthalmol. 2017;2017(11):6824670–6824677.
    1. Sun Y, Zhang B, Jia X, Ling S, Deng J. Efficacy and safety of bevacizumab in the treatment of pterygium: an updated meta-analysis of randomized controlled trials. J Ophthalmol. 2018;2018:4598173–4598179.
    1. Alsmman AH, Radwan G, Abozaid MA, Mohammed UA, Abd Elhaleim NG. Preoperative subconjunctival combined injection of bevacizumab and mitomycin C before the surgical excision of primary pterygium: clinical and histological results. Clin Ophthalmol. 2017;11:493–501.
    1. Yalcin Tok O, Burcu Nurozler A, Ergun G, Akbas Kocaoglu F, Duman S. Topical cyclosporine A in the prevention of pterygium recurrence. Ophthalmologica. 2008;222(6):391–396.
    1. Zhang Q, Bao N, Liang K, Tao L. Adjuvant use of cyclosporine a in the treatment of primary pterygium: a systematic review and meta-analysis. Cornea. 2018;37(8):1000–1007.
    1. Ibáñez M, Eugarrios MF, Calderón DI. Topical cyclosporin A and mitomycin C injection as adjunctive therapy for prevention of primary pterygium recurrence. Ophthalmic Surg Lasers Imaging. 2009;40(3):239–244.
    1. Aydin A, Karadayi K, Aykan U, Can G, Colakoglu K, Bilge AH. Effectiveness of topical ciclosporin A treatment after excision of primary pterygium and limbal conjunctival autograft. J Fr Ophtalmol. 2008;31(7):699–704.
    1. Ren Y, Wang C, Lin Y. Study on topical cyclosporine A in the prevention of pterygium recurrence. Int J Ophthalmol. 2009;9:2240–2241.
    1. Wang IJ, Lai WT, Liou SW, et al. Impression cytology of pterygium. J Ocul Pharmacol Ther. 2000;16(6):519–528.
    1. Nakamura M, Nishida T. Differential effects of epidermal growth factor and interleukin 6 on corneal epithelial cells and vascular endothelial cells. Cornea. 1999;18(4):452–458.
    1. Ebrahimi ME, Kordi-Tamandani DM, Arish M. A novel approach to investigation of the pathogenesis of pterygium based on assessment of promoter hyper-methylation and expression profile of CTLA4 gene: a credible report of CTLA4 gene expression in human eye tissue. Gene. 2016;583(2):130–133.
    1. Lin H, Luo L, Ling S, et al. Lymphatic microvessel density as a predictive marker for the recurrence time of pterygium: a three-year follow-up study. Mol Vis. 2013;19:166–173.
    1. Tang B, Ren H, Liu H, et al. CCR5 blockade combined with cyclosporine A attenuates liver GVHD by impairing T cells function. Inflamm Res. 2016;65(11):917–924.
    1. Kim KW, Kim JC. Current approaches and future directions in the management of pterygium. Int J Ophthalmol. 2018;11(5):709–711.
    1. Hong HS, Lee J, Lee E, et al. A new role of substance P as an injury-inducible messenger for mobilization of CD29(+) stromal-like cells. Nat Med. 2009;15(4):425–435.
    1. Prat D, Zloto O, Ben Artsi E, Ben Simon GJ. Therapeutic contact lenses vs tight bandage patching and pain following pterygium excision: a prospective randomized controlled study. Graefes Arch Clin Exp Ophthalmol. 2018;256(11):2143–2148.
    1. Yeung SN, Lichtinger A, Kim P, et al. Efficacy and safety of patching vs bandage lens on postoperative pain following pterygium surgery. Eye. 2015;29(2):295–296.
    1. Daglioglu MC, Coskun M, Ilhan N, et al. The effects of soft contact lens use on cornea and patient’s recovery after autograft pterygium surgery. Cont Lens Anterior Eye. 2014;37(3):175–177.
    1. Arenas E, Garcia S. A scleral soft contact lens designed for the postoperative management of pterygium surgery. Eye Contact Lens. 2007;33(1):9–12.
    1. Ozcimen M, Sakarya Y, Goktas S, et al. Effect of nepafenac eye drops on pain associated with pterygium surgery. Eye Contact Lens. 2015;41(3):187–189.
    1. Sul S, Korkmaz S, Alacamli G, Ozyol P, Ozyol E. Application of autologous serum eye drops after pterygium surgery: a prospective study. Graefes Arch Clin Exp Ophthalmol. 2018;256(10):1939–1943.
    1. Fonseca EC, Rocha EM, Arruda GV. Comparison among adjuvant treatments for primary pterygium: a network meta-analysis. Br J Ophthalmol. 2018;102(6):748–756.
    1. Bekibele CO, Baiyeroju AM, Olusanya BA, Ashaye AO, Oluleye TS. Pterygium treatment using 5-FU as adjuvant treatment compared to conjunctiva autograft. Eye. 2008;22(1):31–34.
    1. Pherwani A, Vakil V, Eatamadi H, Singh R, Dua HS. Postoperative subconjunctival 5-fluorouracil in the management of recurring pterygium. Br J Ophthalmol. 2007;91(3):398–399.
    1. Rachmiel R, Leiba H, Levartovsky S. Results of treatment with topical mitomycin C 0.02% following excision of primary pterygium. Br J Ophthalmol. 1995;79(3):233–236.
    1. Viani GA, Stefano EJ, de Fendi LI, Fonseca EC. Long-term results and prognostic factors of fractionated strontium-90 eye applicator for pterygium. Int J Radiat Oncol Biol Phys. 2008;72(4):1174–1179.
    1. Jürgenliemk-Schulz IM, Hartman LJ, Roesink JM, et al. Prevention of pterygium recurrence by postoperative single-dose beta-irradiation: a prospective randomized clinical double-blind trial. Int J Radiat Oncol Biol Phys. 2004;59(4):1138–1147.
    1. Zeng W, Liu Z, Dai H, et al. Anti-fibrotic, anti-VEGF or radiotherapy treatments as adjuvants for pterygium excision: a systematic review and network meta-analysis. BMC Ophthalmol. 2017;17(1):211.
    1. Liu J, Fu Y, Xu Y, Tseng SC. New grading system to improve the surgical outcome of multirecurrent pterygia. Arch Ophthalmol. 2012;130(1):39–49.
    1. Olusanya BA, Ogun OA, Bekibele CO, et al. Risk factors for pterygium recurrence after surgical excision with combined conjunctival autograft (CAG) and intraoperative antimetabolite use. Afr J Med Med Sci. 2014;43(1):35–40.
    1. Ha SW, Park JH, Shin IH, Kim HK. Clinical analysis of risk factors contributing to recurrence of pterygium after excision and graft surgery. Int J Ophthalmol. 2015;8(3):522–527.
    1. Sandra S, Zeljka J, Zeljka VA, Kristian S, Ivana A. The influence of pterygium morphology on fibrin glue conjunctival autografting pterygium surgery. Int Ophthalmol. 2014;34(1):75–79.
    1. Varssano D, Shalev H, Lazar M, Fischer N. Pterygium excision with conjunctival autograft: true survival rate statistics. Cornea. 2013;32(9):1243–1250.
    1. Kheirkhah A, Nazari R, Nikdel M, Ghassemi H, Hashemi H, Behrouz MJ. Postoperative conjunctival inflammation after pterygium surgery with amniotic membrane transplantation versus conjunctival autograft. Am J Ophthalmol. 2011;152(5):733–738.
    1. Hilmi MR, Che Azemin MZ, Mohd Kamal K, Mohd Tamrin MI, Abdul Gaffur N, Tengku Sembok TM. Prediction of changes in visual acuity and contrast sensitivity function by tissue redness after pterygium surgery. Curr Eye Res. 2017;42(6):852–856.
    1. Chowers I, Pe’er J, Zamir E, Livni N, Ilsar M, Frucht-Pery J. Proliferative activity and p53 expression in primary and recurrent pterygia. Ophthalmology. 2001;108(5):985–988.
    1. Kase S, Takahashi S, Sato I, Nakanishi K, Yoshida K, Ohno S. Expression of p27(KIP1) and cyclin D1, and cell proliferation in human pterygium. Br J Ophthalmol. 2007;91(7):958–961.
    1. Kim KW, Park SH, Wee SW, Kim JC. Overexpression of angiogenin in pterygium body fibroblasts and its association with proliferative potency. Invest Ophthalmol Vis Sci. 2013;54(9):6355–6362.
    1. Riau AK, Wong TT, Lan W, Finger SN, et al. Aberrant DNA methylation of matrix remodeling and cell adhesion related genes in pterygium. PLoS One. 2011;6(2):e14687.
    1. Chen KH, Hsu WM. Intraoperative ethanol treatment as an adjuvant therapy of pterygium excision. Int J Biomed Sci. 2006;2(4):414–421.
    1. Ashaye AO. Refractive astigmatism and pterygium. Afr J Med Med Sci. 1990;19(3):225–228.
    1. Soriano JM, Janknecht P, Witschel H. Effect of pterygium operation on preoperative astigmatism. Prospective study. Ophthalmologe. 1993;90(6):688–690.
    1. Avisar R, Mekler S, Savir H. Effect of pterygium excision on keratometric readings. Harefuah. 1994;126(2):63–65.
    1. Stern GA, Lin A. Effect of pterygium excision on induced corneal topographic abnormalities. Cornea. 1998;17(1):23–27.
    1. Fong KS, Balakrishnan V, Chee SP, Tan DT. Refractive change following pterygium surgery. Clao J. 1998;24(2):115–117.
    1. Tomidokoro A, Oshika T, Amano S, Eguchi K, Eguchi S. Quantitative analysis of regular and irregular astigmatism induced by pterygium. Cornea. 1999;18(4):412–415.
    1. Kheirkhah A, Safi H, Molaei S, Nazari R, Behrouz MJ, Raju VK. Effects of pterygium surgery on front and back corneal astigmatism. Can J Ophthalmol. 2012;47(5):423–428.
    1. Altan-Yaycioglu R, Kucukerdonmez C, Karalezli A, Corak F, Akova YA. Astigmatic changes following pterygium removal: comparison of 5 different methods. Indian J Ophthalmol. 2013;61(3):104–108.
    1. Gumus K, Erkilic K, Topaktas D, Colin J. Effect of pterygia on refractive indices, corneal topography, and ocular aberrations. Cornea. 2011;30(1):24–29.
    1. Gumus K, Topaktas D, Göktaş A, Karakucuk S, Oner A, Mirza GE. The change in ocular higher-order aberrations after pterygium excision with conjunctival autograft: a 1-year prospective clinical trial. Cornea. 2012;31(12):1428–1431.
    1. Ozgurhan EB, Kara N, Cankaya KI, et al. Corneal wavefront aberrations after primary and recurrent pterygium surgery. Eye Contact Lens. 2015;41(6):378–381.
    1. Razmjoo H, Vaezi M-H, Peyman A, Koosha N, Mohammadi Z, Alavirad M. The effect of pterygium surgery on wavefront analysis. Adv Biomed Res. 2014;3:196.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi